N,N-dimethylglycine 3- (5,6,7,13- tetrahydro- 9- ((1- methylethoxy)methyl)- 5- oxo- 12H- indeno(2,1- a)pyrrolo(3,4- c)carbazol- 12- yl)propyl ester

prodrug of CEP-5214, which has antineoplastic and antiangiogenic activities; inhibits VEGF-R2 tyrosine kinase; structure in first source

Also Known As:

CEP 7055; CEP-7055; CEP7055

Networked: 2 relevant articles (2 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - Carbazoles: 32
        N,N-dimethylglycine 3-(5,6,7,13-tetrahydro-9-((1-methylethoxy)methyl)-5-oxo-12H-indeno(2,1-a)pyrrolo(3,4-c)carbazol-12-yl)propyl ester: 2
  - 3-Ring Heterocyclic Compounds
    - Carbazoles: 32
      - N,N-dimethylglycine 3-(5,6,7,13-tetrahydro-9-((1-methylethoxy)methyl)-5-oxo-12H-indeno(2,1-a)pyrrolo(3,4-c)carbazol-12-yl)propyl ester: 2

Experts

1.	Hunter, Kathryn: 2 articles (07/2006 - 09/2003)
2.	Jones-Bolin, Susan: 2 articles (07/2006 - 09/2003)
3.	Klein-Szanto, Andres: 2 articles (07/2006 - 09/2003)
4.	Ruggeri, Bruce: 2 articles (07/2006 - 09/2003)
5.	Zhao, Hugh: 1 article (07/2006)
6.	Aimone, Lisa: 1 article (09/2003)
7.	Albom, Mark: 1 article (09/2003)
8.	Angeles, Thelma: 1 article (09/2003)
9.	Ator, Mark: 1 article (09/2003)
10.	Bono, Francoise: 1 article (09/2003)

Related Diseases

1.	Neoplasms (Cancer) 09/15/2003 - "Orally administered CEP-7055 has entered Phase I clinical trials in cancer patients." 09/15/2003 - "The antitumor efficacy of chronic CEP-7055 administration was independent of initial tumor volume (in the ASPC-1 pancreatic carcinoma model) and reversible on withdrawal of treatment. " 07/01/2006 - "These studies evaluated the antitumor efficacy of CEP-7055 using orthotopic models of glioblastoma and colon carcinoma in combination with temozolomide, and irinotecan and oxaliplatin, respectively, for their effects on primary and metastatic tumor burden and median survival. " 07/01/2006 - "CEP-7055, a fully synthetic, orally active N,N-dimethylglycine ester of CEP-5214, a C3-(isopropylmethoxy)-fused pyrrolocarbazole with potent pan-vascular endothelial growth factor receptor (VEGFR) kinase inhibitory activity, has recently completed phase I clinical trials in cancer patients. "
2.	Glioblastoma (Glioblastoma Multiforme) 07/01/2006 - "Chronic administration of CEP-7055 (23.8 mg/kg/dose) and temozolomide resulted in improvement of median survival of nude mice bearing orthotopic human glioblastoma xenografts compared with temozolomide alone (261 versus 192 days, respectively; P < or = 0.02). " 07/01/2006 - "The effects of the oral, pan-VEGF-R kinase inhibitor CEP-7055 and chemotherapy in orthotopic models of glioblastoma and colon carcinoma in mice." 07/01/2006 - "These studies evaluated the antitumor efficacy of CEP-7055 using orthotopic models of glioblastoma and colon carcinoma in combination with temozolomide, and irinotecan and oxaliplatin, respectively, for their effects on primary and metastatic tumor burden and median survival. " 07/01/2006 - "These data show the significant efficacy and tolerability of optimal efficacious doses of CEP-7055 when given in combination with temozolomide and irinotecan relative to monotherapy with these cytotoxic agents in preclinical orthotopic glioma and colon carcinoma models and lend support for the use of these treatment regimens in a clinical setting in patients with glioblastoma and colon carcinoma."
3.	Carcinoma (Carcinomatosis) 07/01/2006 - "The effects of the oral, pan-VEGF-R kinase inhibitor CEP-7055 and chemotherapy in orthotopic models of glioblastoma and colon carcinoma in mice." 07/01/2006 - "These studies evaluated the antitumor efficacy of CEP-7055 using orthotopic models of glioblastoma and colon carcinoma in combination with temozolomide, and irinotecan and oxaliplatin, respectively, for their effects on primary and metastatic tumor burden and median survival. " 07/01/2006 - "These data show the significant efficacy and tolerability of optimal efficacious doses of CEP-7055 when given in combination with temozolomide and irinotecan relative to monotherapy with these cytotoxic agents in preclinical orthotopic glioma and colon carcinoma models and lend support for the use of these treatment regimens in a clinical setting in patients with glioblastoma and colon carcinoma."
4.	Pancreatic Neoplasms (Pancreatic Cancer) 09/15/2003 - "The antitumor efficacy of chronic CEP-7055 administration was independent of initial tumor volume (in the ASPC-1 pancreatic carcinoma model) and reversible on withdrawal of treatment. "
5.	Neurologic Manifestations (Neurological Manifestations) 07/01/2006 - "Reductions in neurologic dysfunction, brain edema, hemorrhage, and intratumoral microvessel density (CD34 staining) were observed in glioma-bearing mice receiving CEP-7055 alone, temozolomide alone, and the combination of CEP-7055 and temozolomide relative to vehicle and to temozolomide monotherapy. "

Related Drugs and Biologics

1.	Temozolomide (Temodar)
2.	Oxaliplatin (Eloxatin)
3.	Irinotecan (Camptosar)
4.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
5.	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)
6.	Phosphotransferases (Kinase)
7.	Esters
8.	Cytotoxins (Cytolysins)
9.	3- (5,6,7,13- tetrahydro- 9- ((1- methylethoxy)methyl)- 5- oxo- 12H- indeno(2,1- a)pyrrolo(3,4- c)carbazol- 12- yl)propanol
10.	dimethylglycine

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)